摘要
Purpose:</span></b><span style="font-family:""><span style="font-family:Verdana;"> Prospective study to evaluate the anti-inflammatory efficacy of isotonic seawater solution on metalloproteinase 9 (MMP-9) levels in the tears of patients with dry eye disease (DED). </span><b><span style="font-family:Verdana;">Methods:</span></b><span style="font-family:Verdana;"> A total of 50 patients were included, with the following dry eye criteria in both eyes: InflammaDry</span></span><sup><span style="font-family:Verdana;">?</span></sup><span style="font-family:""><span style="font-family:Verdana;"> test initially positive, ocular surface disease index (OSDI) score ≥ 12 and <33, tear film breakup time (TBUT) ≤ 10 seconds, Shirmer I test result ≤ 10 mm/5 minutes, corneal staining ≥ 1. Additionally, all the patients selected corresponded to a dry eye type 2 - 3 severity degree - mild and moderate - Dry Eye Workshop Study (DEWS) classification. The InflammaDry test is used to measure levels of MMP9 at the beginning and the end of the study. All patients were treated exclusively with isotonic seawater solution 5 times a day for 3 weeks. </span><b><span style="font-family:Verdana;">Results:</span></b><span style="font-family:Verdana;"> The InflammaDry test was positive in 100% of the patients (n = 50) and in 100% (n = 100) of the eyes before treatment. In 14 (28%) patients the test became negative in both eyes, and in 15 (30%) it was negative in one of the eyes. In 43% (n = 43) of the positive eyes, MMP-9 became undetectable in the tear fluid following treatment with isotonic seawater. This change was statistically significant (p < 0.001). </span><b><span style="font-family:Verdana;">Conclusions</span></b><span style="font-family:Verdana;">: The washes with ophthalmic isotonic seawater solution have a significant impact on inflammation of the ocular surface in dry eye disease, with an ability to make MMP-9 levels negative in 43% of cases.
Purpose:</span></b><span style="font-family:""><span style="font-family:Verdana;"> Prospective study to evaluate the anti-inflammatory efficacy of isotonic seawater solution on metalloproteinase 9 (MMP-9) levels in the tears of patients with dry eye disease (DED). </span><b><span style="font-family:Verdana;">Methods:</span></b><span style="font-family:Verdana;"> A total of 50 patients were included, with the following dry eye criteria in both eyes: InflammaDry</span></span><sup><span style="font-family:Verdana;">?</span></sup><span style="font-family:""><span style="font-family:Verdana;"> test initially positive, ocular surface disease index (OSDI) score ≥ 12 and <33, tear film breakup time (TBUT) ≤ 10 seconds, Shirmer I test result ≤ 10 mm/5 minutes, corneal staining ≥ 1. Additionally, all the patients selected corresponded to a dry eye type 2 - 3 severity degree - mild and moderate - Dry Eye Workshop Study (DEWS) classification. The InflammaDry test is used to measure levels of MMP9 at the beginning and the end of the study. All patients were treated exclusively with isotonic seawater solution 5 times a day for 3 weeks. </span><b><span style="font-family:Verdana;">Results:</span></b><span style="font-family:Verdana;"> The InflammaDry test was positive in 100% of the patients (n = 50) and in 100% (n = 100) of the eyes before treatment. In 14 (28%) patients the test became negative in both eyes, and in 15 (30%) it was negative in one of the eyes. In 43% (n = 43) of the positive eyes, MMP-9 became undetectable in the tear fluid following treatment with isotonic seawater. This change was statistically significant (p < 0.001). </span><b><span style="font-family:Verdana;">Conclusions</span></b><span style="font-family:Verdana;">: The washes with ophthalmic isotonic seawater solution have a significant impact on inflammation of the ocular surface in dry eye disease, with an ability to make MMP-9 levels negative in 43% of cases.
作者
Diaz-Llopis Manuel
Pinazo-Duran Maria Dolores
Diaz-Guiñon Loreto
Rahhal-Ortuño Miriam
Gallego-Pinazo Roberto
Dolz-Marco Rosa
Diaz-Guiñon Teresa
Diaz Maria
Romero Francisco Javier
Diaz-Llopis Manuel;Pinazo-Duran Maria Dolores;Diaz-Guiñon Loreto;Rahhal-Ortuño Miriam;Gallego-Pinazo Roberto;Dolz-Marco Rosa;Diaz-Guiñon Teresa;Diaz Maria;Romero Francisco Javier(University of Valencia, Valencia, Spain;Ophthalmology Unit, Faculty of Medicine, University of Valencia, Valencia, Spain;Molecular Ophthalmology Unit, Faculty of Medicine, University of Valencia, Valencia, Spain;Consellería de Sanitat (Valencian Regional Health Ministry), Valencian Autonomous Government, Valencia;IOVA-Valencia Ophthalmology Institute, Valencia, Spain;Doctor Peset University Hospital, Valencia, Spain;Santiago Grisolía Eye Research Laboratory, FISABIO, Valencia, Spain;Department of Ophthalmology, La Fe Hospital, Valencia, Spain;IMED Hospital, Valencia, Spain)
